← Leaderboards
Stephen H Safe
Texas A&M University
$17,757,115
Attributed
$24,083,507
Total exposure
22
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,813,508 · 24
By mechanism
R01$18,973,252 · 15
P42$11,072,596 · 3
P30$6,476,502 · 3
T32$1,721,928 · 1
R21$569,230 · 2
Top collaborators
- Arul Jayaraman16 shared
- Robert Stephen Chapkin15 shared
- Clinton D Allred5 shared
- Kyongbum Lee4 shared
- Maen Abdelrahim3 shared
- James Jing Cai3 shared
- Andrei M Mikheev3 shared
- Robert C Rostomily3 shared
Most similar at Texas A&M University
Same institution · by research overlap
- Maen Abdelrahim$566,889
- James Jing Cai$758,576
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoResponseLigandsGenesReceptorCellsMediatingGene ExpressionBaseCell LineCancer CellPathway InteractionsEstrogen ReceptorsLaboratoriesIndolesPharmaceutical PreparationsMalignant NeoplasmsTranscription FactorLinkXenograft ProcedureExhibitsDietTissuesPrograms
Grant awards (115)
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance$571,380
R01 · FY2025 · CA · contact PI
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$554,314
R01 · FY2025 · NS
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance$543,717
R01 · FY2024 · CA · contact PI
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$511,747
R01 · FY2024 · NS
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance$585,570
R01 · FY2023 · CA · contact PI
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$503,363
R01 · FY2023 · NS
Pilot Project Program$318,901
P30 · FY2023 · ES · contact PI
Pilot Project Program$318,408
P30 · FY2022 · ES · contact PI
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut$339,449
R01 · FY2021 · AT · contact PI
Pilot Project Program$318,408
P30 · FY2021 · ES · contact PI
Microbial flavonoid metabolites as modulators of AD markers in a 3D human neural tissue model$385,050
R01 · FY2020 · AT · contact PI
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut$346,068
R01 · FY2020 · AT · contact PI
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions$318,589
R01 · FY2020 · ES
Pilot Project Program$317,095
P30 · FY2020 · ES · contact PI
Diet induced modifications of microbiota metabolites in colon tumorigenesis$99,770
R01 · FY2020 · CA
Diet induced modifications of microbiota metabolites in colon tumorigenesis$479,666
R01 · FY2019 · CA
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions$421,647
R01 · FY2019 · ES
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut$354,277
R01 · FY2019 · AT · contact PI
Pilot Project Program$314,110
P30 · FY2019 · ES · contact PI
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut$150,001
R01 · FY2019 · AT · contact PI
Diet induced modifications of microbiota metabolites in colon tumorigenesis$484,425
R01 · FY2018 · CA
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions$411,549
R01 · FY2018 · ES
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut$374,064
R01 · FY2018 · AT · contact PI
Diet induced modifications of microbiota metabolites in colon tumorigenesis$477,180
R01 · FY2017 · CA
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions$415,336
R01 · FY2017 · ES
Diet induced modifications of microbiota metabolites in colon tumorigenesis$438,596
R01 · FY2016 · CA
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions$395,905
R01 · FY2016 · ES
Pilot Project$200,386
P30 · FY2016 · ES · contact PI
Cytosolic Ah Receptor: Mechanism of Action$181,164
R21 · FY2016 · ES · contact PI
Cytosolic Ah Receptor: Mechanism of Action$218,148
R21 · FY2015 · ES · contact PI
Pilot Project$159,721
P30 · FY2015 · ES · contact PI
Molecular Mechanisms and Application of Ah Receptor-MicroRNA Interactions$251,424
R01 · FY2014 · CA · contact PI
Pilot Project$163,930
P30 · FY2014 · ES · contact PI
MicroRNAs as Targets for Colon Cancer Chemotherapy$244,171
R01 · FY2013 · CA · contact PI
Molecular Mechanisms and Application of Ah Receptor-MicroRNA Interactions$243,648
R01 · FY2013 · CA · contact PI
MicroRNAs as Targets for Colon Cancer Chemotherapy$259,757
R01 · FY2012 · CA · contact PI
Molecular Mechanisms and Application of Ah Receptor-MicroRNA Interactions$259,200
R01 · FY2012 · CA · contact PI
MicroRNAs as Targets for Colon Cancer Chemotherapy$259,757
R01 · FY2011 · CA · contact PI
Molecular Mechanisms and Application of Ah Receptor-MicroRNA Interactions$259,200
R01 · FY2011 · CA · contact PI
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy$214,525
R01 · FY2011 · CA · contact PI
Molecular Mechanisms and Application of Ah Receptor-MicroRNA Interactions$267,216
R01 · FY2010 · CA · contact PI
MicroRNAs as Targets for Colon Cancer Chemotherapy$237,391
R01 · FY2010 · CA · contact PI
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy$221,160
R01 · FY2010 · CA · contact PI
MicroRNAs as Targets for Colon Cancer Chemotherapy$237,391
R01 · FY2009 · CA · contact PI
Colon Cancer Inhibition by a Class of PPARgamma Agonists$226,255
R01 · FY2009 · CA · contact PI
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy$221,160
R01 · FY2009 · CA · contact PI
Procedures to Assess the Hazards of a Superfund Site$50,264
P42 · FY2009 · ES · contact PI
Procedures to Assess the Hazards of a Superfund Site$400,000
P42 · FY2008 · ES · contact PI
Inhibition of Pancreatic Cancer by New PPARgamma Agonis*$241,787
R01 · FY2008 · CA · contact PI
Colon Cancer Inhibition by a Class of PPARgamma Agonists$226,255
R01 · FY2008 · CA · contact PI
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy$203,700
R01 · FY2008 · CA · contact PI
Alcoholic Hepatitis: Molecular Mechanisms$169,918
R21 · FY2008 · AA · contact PI
Procedures to Assess the Hazards of a Superfund Site$42,000
P42 · FY2008 · ES · contact PI
Procedures to Assess the Hazards of a Superfund Site$1,496,036
P42 · FY2007 · ES · contact PI
Colon Cancer Inhibition by a Class of PPARgamma Agonists$226,255
R01 · FY2007 · CA · contact PI
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy$203,700
R01 · FY2007 · CA · contact PI
Inhibition of Pancreatic Cancer by New PPARgamma Agonis*$203,615
R01 · FY2007 · CA · contact PI
Endocrine Disruptors$153,800
P42 · FY2007 · ES · contact PI
Toxicology of Environment Contaminants$62,169
T32 · FY2007 · ES · contact PI
Procedures to Assess the Hazards of a Superfund Site$46,296
P42 · FY2007 · ES · contact PI
Procedures to Assess the Hazards of a Superfund Site$1,467,400
P42 · FY2006 · ES · contact PI
Center for Rural and Environmental Health$1,442,336
P30 · FY2006 · ES · contact PI
Toxicology of Environment Contaminants$273,770
T32 · FY2006 · ES · contact PI
Coactivation of Estrogen Receptor alpha/Sp1$223,778
R01 · FY2006 · CA · contact PI
Colon Cancer Inhibition by a Class of PPARgamma Agonists$223,778
R01 · FY2006 · CA · contact PI
2,3,7,8,--TCDD Effects on the Estrogenic Responses$213,121
R01 · FY2006 · ES · contact PI
Mechanisms of Growth Factor-Estrogen Receptor Crosstalk$213,121
R01 · FY2006 · ES · contact PI
Inhibition of Pancreatic Cancer by New PPARgamma Agonis*$210,424
R01 · FY2006 · CA · contact PI
Endocrine Disruptors$139,866
P42 · FY2006 · ES · contact PI
2nd International Conference on Environmental Health in Central & Eastern Europe$24,500
P42 · FY2006 · ES · contact PI
Procedures to Assess the Hazards of a Superfund Site$16,840
P42 · FY2006 · ES · contact PI
2nd International Conference on Environmental Health in Central &Eastern Europe$1,600,140
P42 · FY2005 · ES
Toxicology of Environment Contaminants$271,070
T32 · FY2005 · ES
Coactivation of Estrogen Receptor alpha/Sp1$229,163
R01 · FY2005 · CA
Colon Cancer Inhibition by a Class of PPARgamma Agonists$229,163
R01 · FY2005 · CA
Mechanisms of Growth Factor-Estrogen Receptor Crosstalk$218,250
R01 · FY2005 · ES
2,3,7,8,--TCDD Effects on the Estrogenic Responses$218,250
R01 · FY2005 · ES
Inhibition of Pancreatic Cancer by New PPARgamma Agonis*$204,593
R01 · FY2005 · CA
Endocrine Disruptors$136,751
P42 · FY2005 · ES
Administrative Core$57,326
P42 · FY2005 · ES
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$1,099,225
P42 · FY2004 · ES
Toxicology of Environment Contaminants$282,150
T32 · FY2004 · ES
Coactivation of Estrogen Receptor alpha/Sp1$229,163
R01 · FY2004 · CA
Mechanisms of Growth Factor-Estrogen Receptor Crosstalk$218,250
R01 · FY2004 · ES
2,3,7,8,--TCDD Effects on the Estrogenic Responses$218,250
R01 · FY2004 · ES
Inhibition of Pancreatic Cancer by New PPARgamma Agonis*$216,377
R01 · FY2004 · CA
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$89,424
P42 · FY2004 · ES
Center for Rural and Environmental Health$1,441,979
P30 · FY2003 · ES
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$1,067,309
P42 · FY2003 · ES
Toxicology of Environment Contaminants$273,437
T32 · FY2003 · ES
2,3,7,8,--TCDD Effects on the Estrogenic Responses$218,250
R01 · FY2003 · ES
Mechanisms of Growth Factor-Estrogen Receptor Crosstalk$218,250
R01 · FY2003 · ES
Center for Rural and Environmental Health$50,000
P30 · FY2003 · ES
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$19,700
P42 · FY2003 · ES
Center for Rural and Environmental Health$1,431,228
P30 · FY2002 · ES
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$1,035,230
P42 · FY2002 · ES
Toxicology of Environment Contaminants$246,744
T32 · FY2002 · ES
Mechanisms of Growth Factor-Estrogen Receptor Crosstalk$218,250
R01 · FY2002 · ES
2,3,7,8,--TCDD Effects on the Estrogenic Responses$218,250
R01 · FY2002 · ES
Endocrine disruptors--Mechanistic studies$73,465
P42 · FY2002 · ES
ESTROGEN INDUCED RESPONSES VIA ER/SPL COMPLEXES$25,026
R01 · FY2002 · CA
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$955,047
P42 · FY2001 · ES
2, 3, 7, 8--TCDD EFFECTS ON ESTROGENIC RESPONSES$183,168
R01 · FY2001 · ES
MECHANISMS OF GROWTH FACTOR/ESTROGEN RECEPTOR CROSSTALK$148,774
R01 · FY2001 · ES
ESTROGEN INDUCED RESPONSES VIA ER/SPL COMPLEXES$133,932
R01 · FY2001 · CA
TOXICOLOGY OF ENVIRONMENT CONTAMINANTS$113,453
T32 · FY2001 · ES
ALKYL PCDFS--INHIBITION OF MAMMARY CANCER$112,081
R01 · FY2001 · CA
Endocrine disruptors--Mechanistic studies$73,465
P42 · FY2001 · ES
PROCEDURES TO ASSESS THE HAZARDS OF A SUPERFUND SITE$955,047
P42 · FY2000 · ES
TOXICOLOGY OF ENVIRONMENT CONTAMINANTS$199,135
T32 · FY2000 · ES
2, 3, 7, 8--TCDD EFFECTS ON ESTROGENIC RESPONSES$177,832
R01 · FY2000 · ES
MECHANISMS OF GROWTH FACTOR/ESTROGEN RECEPTOR CROSSTALK$144,817
R01 · FY2000 · ES
ESTROGEN INDUCED RESPONSES VIA ER/SPL COMPLEXES$130,893
R01 · FY2000 · CA
ALKYL PCDFS--INHIBITION OF MAMMARY CANCER$108,818
R01 · FY2000 · CA
Endocrine disruptors--Mechanistic studies$73,465
P42 · FY2000 · ES